Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Business Segments — Provision for income taxes

Similar metrics at other companies

Target logo
TGTReportable Segment — Provision for income taxes
$252M-27.2%
Adobe logo
ADBEReportable Segment — Provision for income taxes
$526M+28.3%
Samsara logo
IOTReportable Segment — Provision for income taxes
$4.42M+178%
Zoom Video Communications, Inc. logo
ZMReportable Segment — Provision for income taxes
$105.94M+73.2%
Biohaven logo
BHVNReportable Segment — Provision for income taxes
$272K-55.3%
DocuSign logo
DOCUReportable Segment — Provision for income taxes
$39.56M+2,223%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.84B+34.5%
Enterprise value$2.73B+30.6%
P/S4.7×-2.5×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other reconciling items(1)1,3571,8445123,004
Net loss$(18,551)$(20,340)$(25,518)$(45,460)
Other segment disclosures:
Interest income$3,698$4,229$7,420$7,683
Interest expense$(2,156)$(2,240)$(4,284)$(4,453)
Depreciation and amortization expense$(1,000)$(453)$(1,437)$(913)
Provision for income taxes$(2,716)$(5,068)
(1) Other reconciling items primarily includes interest income, gain on exchange of long-term investments, interest expense, and provision for income taxes.

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s business segments — provision for income taxes?
Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — provision for income taxes of -$2.72M in Q2 2026.
What does business segments — provision for income taxes mean?
This metric represents the estimated income tax expense recognized by the business segment based on its taxable earnings for the reporting period. It accounts for both current tax liabilities and deferred tax impacts resulting from temporary differences between financial reporting and tax regulations. Understanding this provision is critical for assessing the segment's effective tax rate and its impact on net profitability.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — provision for income taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude